Study design
PK/PD
SOLID TUMORS
This was a single-arm, phase I, open-label study conducted at two participating hospitals in China (ClinicalTrials.gov identifier: NCT04258527), which aimed to evaluate PK/PD characteristics, and preliminary safety and antitumor activity of pemigatinib in Chinese patients with FGF/FGFR1-3 altered, advanced solid tumors.